Persistent de Quervain tenosynovitis induced by somatotropin treatment

Yurdakul O. V., Ayture L., YALCINKAYA E. Y.

JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, vol.30, no.11, pp.1223-1226, 2017 (SCI-Expanded) identifier identifier identifier


Background: Growth hormone deficiency is a well-known clinical entity that is usually treated with somatotropin (growth hormone). Growth hormone has some frequent side effects such as intracranial hypertension, lymphedema and diabetes mellitus.